BFA
DNA icon

Beaumont Financial Advisors’s Ginkgo Bioworks DNA Stock Holding History

Beaumont Financial Advisors’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-625
Closed -$8.36K – 359
2024
Q2 		$8.36K Buy
625
+125
+25% +$3.73K ﹤0.01% 365
2024
Q1 		$23.2K Buy
500
+125
+33% +$6.47K ﹤0.01% 361
2023
Q4 		$25.4K Hold
375
– – ﹤0.01% 340
2023
Q3 		$27.1K Hold
375
– – ﹤0.01% 322
2023
Q2 		$27.9K Buy
375
+50
+15% +$2.96K ﹤0.01% 341
2023
Q1 		$17.3K Buy
325
+25
+8% +$1.58K ﹤0.01% 314
2022
Q4 		$20.3K Buy
300
+25
+9% +$2.3K ﹤0.01% 313
2022
Q3 		$34K Buy
275
+25
+10% +$2.98K ﹤0.01% 302
2022
Q2 		$24K Buy
+250
New +$30.5K ﹤0.01% 304

Other funds holding DNA

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Beaumont Financial Advisors's DNA Position: Q3 2024 in Review

Beaumont Financial Advisors sold out of Ginkgo Bioworks (DNA) in Q3 2024, closing a stake of 625 shares — an estimated $8.36K sold.

Beaumont Financial Advisors first reported a position in DNA in Q2 2022 and held it in 9 quarters. The position peaked at $34K in Q3 2022. 159 funds tracked by Wall St. Rank hold DNA as of Q3 2024.

  • Beaumont Financial Advisors reported no remaining Ginkgo Bioworks position as of Q3 2024 after selling out during the quarter.
  • Beaumont Financial Advisors sold 625 Ginkgo Bioworks shares in Q3 2024, an estimated $8.36K.
  • Beaumont Financial Advisors first reported a position in Ginkgo Bioworks in Q2 2022 and held it in 9 quarters.
  • Beaumont Financial Advisors's Ginkgo Bioworks position peaked at $34K in Q3 2022.
  • 159 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q3 2024.

Based on Beaumont Financial Advisors's 13F filing for Q3 2024, filed 9 Oct 2024.